Rituximab – Targeted Monoclonal Antibody Therapy
Rituximab is a biologic medicine classified as a chimeric monoclonal antibody designed to target and bind the CD20 protein found on the surface of B-lymphocytes (B cells), a type of white blood cell. By specifically recognizing this protein, Rituximab helps eliminate disease-causing B cells while preserving other vital immune cells, making it a powerful agent in both oncology and certain immune-mediated conditions.
How Rituximab Works
Rituximab binds to the CD20 antigen on B cells, signaling the body’s immune system to destroy these cells. It acts through multiple mechanisms, including:
-
Antibody-dependent cellular cytotoxicity (ADCC) – attracts immune cells to kill the targeted cells
-
Complement-dependent cytotoxicity (CDC) – activates the complement cascade to break down cell membranes
-
Direct cell death induction – triggers apoptosis in CD20-positive cells
These targeted actions allow Rituximab to reduce harmful B cells while minimizing broader immune suppression.
Indications & Clinical Use
Rituximab is widely used in the treatment of conditions where CD20-positive B cells play a key role, including:
-
Non-Hodgkin’s lymphoma (NHL), both as a single agent and in combination with chemotherapy
-
Chronic lymphocytic leukemia (CLL) with chemotherapy regimens
-
Certain autoimmune diseases, such as rheumatoid arthritis when other treatments have failed
-
Vasculitides like granulomatosis with polyangiitis and microscopic polyangiitis
-
Additional immune-mediated conditions as determined by clinicians
Brand formulations include Rituxan, Riabni, Ruxience, and Truxima.
Administration
Rituximab is administered by a qualified healthcare professional, most commonly through intravenous (IV) infusion. The dosing schedule varies depending on the condition being treated and the patient’s overall health profile. Close monitoring during administration ensures patient safety and optimal therapeutic response.
Key Benefits
-
Targeted action: Specifically eliminates CD20-positive B cells
-
Versatile clinical use: Effective in both cancer and autoimmune conditions
-
Well-studied: Long history of clinical evidence supporting safety and efficacy
